What are the current guidelines for timing repeat dual‑energy X‑ray absorptiometry (DEXA) scans and associated laboratory evaluations in patients with osteopenia or osteoporosis?

Repeat DEXA Timing in Osteoporosis and Osteopenia

Repeat DEXA scans should be performed every 1-5 years after starting or changing therapy, with intervals individualized based on baseline T-score, treatment status, and fracture risk—not routinely before 23 months unless clinically indicated. 1

When to Order Initial DEXA Screening

The most recent guideline consensus recommends:

• All women ≥65 years 1
• All men >70 years 1
• Women and men ≥50 years with osteoporosis risk factors (prior fracture, glucocorticoid use, secondary causes) 1

Timing of Repeat DEXA Scans

General Framework

The 2025 European guideline establishes that follow-up intervals typically range from 1-5 years after starting or changing therapy, influenced by clinical state, national guidelines, and reimbursement 1. The 2024 ISCD positions emphasize that repeat DXA should only be performed when results would impact patient management and with pre-defined objectives 2.

Specific Clinical Scenarios

For patients on osteoporosis treatment:

• Testing intervals of 1-2 years are appropriate for high-risk patients (T-score <-2.5, active treatment, glucocorticoid use) 3
• Repeat BMD is useful to assess treatment response, as fracture reduction is proportional to BMD change 4
• Avoid testing intervals <23 months unless there is compelling clinical indication, as this represents "intensive testing" that has appropriately declined in practice 3

For untreated osteopenia:

• Longer intervals (2-5 years) are reasonable for monitoring progression 1
• Frequency should increase with higher baseline fracture risk

After treatment discontinuation:

• Repeat BMD measurement is specifically indicated to guide decisions about restarting therapy 4

Critical Technical Requirement

Each facility must determine its precision error and calculate the least significant change (LSC) to interpret whether BMD changes are real versus measurement variability 1. Follow-up scans should ideally use the same DXA system at the same facility to minimize technical error 1.

Anatomic Sites to Measure

Perform DXA at:

• Lumbar spine
• Total hip
• Femoral neck
• One-third radius (if indicated, particularly for hyperparathyroidism or when other sites cannot be measured) 1

Use the lowest T-score from any measured site for diagnosis 1.

Vertebral Fracture Assessment (VFA)

Consider VFA or standard radiography in patients ≥50 years with:

• T-score <-1.0
• Historical height loss >4 cm
• Self-reported vertebral fracture
• Long-term glucocorticoid therapy 1

This is critical because prevalent vertebral fractures change management even when BMD is not in the osteoporotic range.

Common Pitfalls to Avoid

1. Ordering repeat DEXA too frequently (<23 months): Real-world data shows this practice appropriately declined from 16.7% in 2006 to 6.7% in 2015, as it rarely provides actionable information 3

2. Failing to establish baseline precision: Without knowing your facility's LSC, you cannot determine if BMD changes are clinically meaningful 1

3. Switching DXA machines between scans: This introduces measurement error that can obscure real changes 1

4. Ordering repeat scans without a management question: The 2024 ISCD positions emphasize testing only when results will impact decisions 2

Evidence Quality Considerations

The 2025 European guideline 1 represents the most current consensus and should frame all decisions. The 2024 ISCD positions 2 provide complementary expert guidance emphasizing clinical context. Real-world practice data 3 confirms that clinicians appropriately reserve more frequent testing for highest-risk patients (those with T-scores <-2.5, on treatment, or using glucocorticoids).

The key paradigm shift is away from routine fixed-interval testing toward risk-stratified, objective-driven repeat imaging.